Merck and Endocyte’s ovarian cancer drug fails in trialReuters(Reuters) – Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening. The trial was testing the drug, vintafolide, in combination …Endocyte Reports First Quarter Financial Results and Provides Clinical UpdateMarketWatchEndocyte, Inc. (ECYT) Tops Q1 EPS by 5c; Reports Halt of PROCEED Trial (MRK)StreetInsider.com (subscription)Endocyte (ECYT) Releases Quarterly Earnings Results, Beats Estimates By …Zolmaxall 4 news articles …Read Full Story
Merck and Endocyte's ovarian cancer drug fails in trial - Reuters
Real Estate of Cebu
